AFFISE
24.2.2021 14:02:11 CET | Business Wire | Press release
Affise , the global technology leader in partnerships management and automation, today announced a Series A funding round worth $8 million. This recent funding round, led by Leta Capital and TMT Investments, follows a period of impressive growth for the company. Founded in Vilnius, Lithuania in 2016, Affise has doubled its revenue every year and now employs over 120 professionals in six offices around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005005/en/
“Affise has shown remarkable international growth, which we are happy to intensify even further with the investment round,” said Alexander Chachava, Managing partner at Leta Capital. “We can see that performance marketing becomes essential across many new channels which were difficult to measure until recently. The company empowers its clients with the real tools to boost the business, and we believe that Affise is going to become an industry-standard in performance marketing automation software.”
“The funding round will help the team focus on geographic expansion in regions where advertising, affiliate marketing and economy as a whole are growing, namely the States and Asian countries. With such a great team and product, we believe in success,” - commented Artyom Inyutin, Co-founder & Head of Investments, TMT Investments.
As the partnership marketing industry continues an impressive growth of 10%, every year, its 2021 value is estimated to reach $1.2B. Affise endeavours to utilize the funding to expand its product suite, providing marketers with a single platform to automate and scale partnerships. Following a tremendous success entering the Chinese market in 2019, Affise plans to increase its presence in North America, LatAm, and SEA, as well as cement its leadership in Europe, Israel and India.
“Partnerships management is becoming the vital component of the marketing technology stack, and Affise has established itself as a leader in this fast-growing category,” said Stanislau Litvinau, CEO and Co-Founder, Affise. “Our commitment to representing the marketers’ interests has gained the trust of the leading agencies and networks, and we see significant potential to capture additional opportunity in the market. One strategy we’re aiming to complete with this funding is entering the adjacent market of direct advertisers and brands, empowering them to grow their marketing channel with affiliate programs”.
Affise works with over 1,000 customers, including leading brands and agencies such as Wargaming, Xapads, Hypercentage, Kismia, Mobavenue, Zorka.Mobi, Mobligent. The company boasts connections to a conglomerate of over 300,000 partners, which accelerates business growth. The winner of 14 awards in the last year alone, Affise has been crowned the leader in three categories by G2: Partner Management, Marketing Analytics, and Digital Analytics.
“The market evolution from traditional affiliates to new performance channels (influencers, brand-to-brand and other), along with the skyrocketing growth in e-Commerce in 2020, will encourage more small and medium advertisers to launch their affiliate programs'' - Dmitrii Zotov, CTO and Co-Founder, Affise. “This trend will generate demand for technological solutions to start and manage affiliate programs from scratch and achieve incremental growth. Thus, this funding round will enable us to follow Affise’s mission of empowering marketers with the tools needed to catapult their success and make accurate strategic decisions. This will drive innovations and transparency across the industry”.
About Affise
Affise is a partnership marketing platform for brands, advertisers and agencies to automate and scale their partner relations via all possible performance marketing channels: traditional affiliates, influencers, networks and agencies. The synergy of technology and the long standing experience allows Affise’s clients to make partnerships manageable and revenue predictable marketing channel. To learn more, visit www.affise.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005005/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
